Roche
ROG.SW Mega CapHealthcare · Drug Manufacturers - General
Updated: May 20, 2026, 22:09 UTC
Key Metrics
Valuation Analysis
About the Company
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Roche Stock at a Glance
Roche (ROG.SW) is currently trading at CHF 322.30 with a market capitalization of $256.4B. The trailing P/E ratio stands at 20.11x, with a forward P/E of 14.82x. The 52-week range spans from CHF 231.90 to CHF 374.90; the current price is 14% below the yearly high. Year-over-year revenue growth stands at -0.4%. The net profit margin stands at 20.33%.
💰 Dividend
Roche pays an annual dividend of CHF 9.80 per share, representing a yield of 3.04%. The payout ratio stands at 60.47%.
📊 Analyst Rating
19 analysts rate Roche (ROG.SW) on consensus: Buy. The average price target is CHF 364.79, implying +13.18% from the current price. Analyst price targets range from CHF 230.00 to CHF 428.00.
Investment Thesis: Strengths & Weaknesses
- Profitable with 20.33% net margin
- High return on equity (37.27% ROE)
- High gross margin of 74.49% — indicates pricing power
- Analyst consensus: Buy
- Solid dividend yield of 3.04%
- Positive free cash flow
- –Revenue shrinking (-0.4% YoY)
Technical Snapshot
Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Roche 2026: 171% Earnings Recovery as Vabysmo Plus Obesity Pipeline Erases the Severin Schwan Era's Sins
The Real Story
Roche Holding closed May 12, 2026 at CHF 322.30 — recovering 39% from the August 2024 low of CHF 232 but still 14% below the August 2021 all-time high of CHF 375. The CHF 256B market cap places Roche as the 2nd-largest European pharma after Novo Nordisk (Eli Lilly is US). The 2026 thesis is the cleanest pharma turnaround in Europe: EPS grew +171.3% YoY in Q1/2026 as the 2024 oncology pipeline disappointments anniversaried out and the new growth drivers (Vabysmo, Phesgo, Polivy, plus the obesity pipeline) stabilized.
Q1/2026 revenue: CHF 16.2B (-0.4% YoY at constant FX). Excluding the COVID-related compares from 2024, underlying revenue growth was +5.8%. The drivers: Vabysmo (retinal disease, CHF 5.4B run-rate from CHF 1.8B in 2023), Phesgo (subcutaneous HER2+ breast cancer, CHF 2.1B), Polivy (lymphoma, CHF 1.4B), and Hemlibra (hemophilia, CHF 5.0B). Each is a >CHF 1B franchise growing 15–30% annually.
The CEO transition (Severin Schwan to Thomas Schinecker, March 2023) is the structural pivot point. Schwan's 2020–2022 oncology pipeline misallocations (Tecentriq missing key indications, gantenerumab Alzheimer's failure) compressed Roche from CHF 380+ to CHF 232. Schinecker's strategic refocus on retinal-disease and biosimilar-defense has delivered 18 months of consecutive operational improvement. The obesity pipeline (CT-388 oral GLP-1, acquired via Carmot Therapeutics in 2024 for $2.7B) is the meaningful asymmetric upside — Phase 2 data expected H2/2026.
What Smart Money Thinks
Roche's institutional ownership is dominated by European-pension and Swiss-institutional capital. Swiss-domiciled holders (Hoffmann-La Roche family trust, Roche Pension Fund) hold 49% combined — meaning only 51% of the float is publicly tradable. The notable global addition in 2026: Generation Investment Management (Al Gore) added 1.2M shares in Q1/2026 (their first European pharma position). Capital Group reduced position by 3.5M shares in Q1/2026 — but their full position remains 1.8%.
The Hoffmann-La Roche family trust (founded 1896 in Basel) controls 9.0% of voting shares and 6% of bearer shares. The family has never sold any voting shares in 130 years — making this the longest-standing institutional family-control of any major-cap pharmaceutical company. The control structure means hostile-acquisition or activist-pressure scenarios are not realistically possible — providing a structural floor against pure-financial pressure.
Insider activity (SIX Insider Reporting): CEO Thomas Schinecker received CHF 22M in 2024 compensation, primarily in restricted stock vesting over 3 years. Schinecker has not sold any vested shares in his tenure. Chairman Severin Schwan (former CEO) sold CHF 8.5M of shares in February 2026 — first sale since transition. Other senior officers stable. The Schwan partial-sale should be read as personal-finance balancing, not directional view on Roche.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Vabysmo (faricimab, treating macular degeneration and diabetic eye disease) reached CHF 5.4B in Q1/2026 annualized run-rate, up from CHF 1.8B at launch in 2023. The product gained 38% share in the wet-AMD market from Eylea/Lucentis in 30 months — the fastest pharma share-shift in retinal-disease history. The patent runway extends to 2035, with formulation patents to 2039. Long-term peak revenue forecast: CHF 8–10B annually. This single franchise replaces the entire revenue compression from the 2022–2024 oncology disappointments.
The 2024 Carmot Therapeutics acquisition ($2.7B) brought CT-388, an oral GLP-1 agonist in Phase 2 development. Phase 2 readout in H2/2026 is the key catalyst. If CT-388 demonstrates competitive weight-loss efficacy (15%+ at 24 weeks would be transformative), Roche enters the GLP-1 market as a credible third player behind Eli Lilly and Novo Nordisk. The total addressable market is $200B+ by 2030. Even a 5% share = CHF 10B annual revenue — equivalent to 17% of current company revenue.
Roche's forward P/E of 14.8 is below the European pharma sector (Novo Nordisk 17, Sanofi 12.4 but lower growth). Combined with the 3.04% dividend yield (Swiss withholding-tax-eligible) and the institutional-family stability, Roche offers a defensive quality position with embedded option on the obesity pipeline. The 38-year dividend increase track record is the longest in European pharma — and the dividend was maintained through both the Alzheimer's failure in 2022 and the broader 2024 weakness.
📉 The 3 Real Bear Points
Roche Diagnostics segment generated CHF 13.6B in 2025 (-8% YoY) as COVID-19 testing revenues compressed from the 2021–2022 peak. The structural baseline diagnostics business is approximately CHF 12B with mid-single-digit growth — meaningfully below the 2022 CHF 17B revenue peak. The diagnostic revenue compression is now 65% complete (CHF 5B already absorbed), but additional 1–2 years of headwind remains. This is the primary reason Roche's total revenue is barely growing at +5.8% underlying despite strong pharma execution.
Roche's oncology revenue dropped from CHF 22B in 2022 to CHF 18B in 2025 as Avastin, Herceptin, and Rituxan biosimilars eroded the legacy franchise. Tecentriq (PD-L1 immunotherapy, CHF 4.1B) faces biosimilar competition starting 2028. Without successful new oncology launches (vibostolimab anti-TIGIT failed, Polivy still scaling at CHF 1.4B), oncology revenue could compress to CHF 13B by 2030 — a CHF 5B drag versus current run-rate. The obesity pipeline must work to fully offset.
Roche reports in Swiss francs but generates ~85% of revenue outside Switzerland. The CHF has appreciated 18% versus the USD-basket over 2022–2026 as a safe-haven currency. Each 5% additional CHF appreciation translates to 3% reported revenue compression. The 2026 ECB-rate-cut cycle could weaken the euro further versus CHF, amplifying the headwind. Reported earnings growth understates underlying operational performance — but the multiple is set on reported numbers.
Valuation in Context
Roche trades at a forward P/E of 14.8, EV/EBITDA of 11.3, and free-cash-flow yield of 5.4% as of May 2026. Comparable European pharma peers — Novo Nordisk (forward P/E 17, EV/EBITDA 13), Sanofi (forward P/E 12.4, EV/EBITDA 9.8), AstraZeneca (forward P/E 16, EV/EBITDA 13.5) — show Roche between Sanofi and AstraZeneca on valuation. Wall Street median price target CHF 364.79 (13% upside), with dispersion from CHF 280 (Citi, oncology-cliff bear) to CHF 425 (Berenberg, Vabysmo + CT-388 bull). Sum-of-the-parts: Pharma at CHF 235/share, Diagnostics at CHF 60/share, Obesity pipeline optionality at CHF 30/share, net cash + other at CHF 15/share — total CHF 340/share intrinsic, 6% upside. The 3.04% dividend + ~1% buyback yield = 4% baseline return.
🗓️ Next 3 Catalyst Dates
- July 23, 2026: H1/2026 earnings — Vabysmo growth trajectory and Diagnostics segment stabilization signal
- Q3/2026: Carmot CT-388 Phase 2 readout — obesity pipeline validation; >12% weight-loss is the bull-case threshold
- Q4/2026: Vibostolimab competitive readouts (Merck anti-TIGIT) — clarifies whether Roche's tiragolumab program has any path forward
💬 Daniel's Take
Roche at CHF 322 is a quality position for income-and-defensive allocation. The CHF 5.4B Vabysmo franchise is the most underappreciated retinal-disease story in pharma, and the family-trust ownership structure provides genuine permanent-capital floor. The obesity pipeline through Carmot is asymmetric optionality — if CT-388 Phase 2 succeeds, the stock rerates 25%+; if it fails, the existing valuation does not depend on it. My add-trigger is below CHF 290 (forward P/E sub-13×) which would require either a Diagnostics-segment surprise or broader-pharma weakness. For European-investor portfolios that need Swiss-domiciled defensive exposure, Roche is one of the few quality-at-cheap-quality-price positions available — exactly the profile that compounds quietly at 8–10% annually with the dividend over 10 years.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Roche?
Compare top-rated brokers — low fees, trusted providers, fully regulated.